The IBD market is set to soar to $32B. AbbVie could be the big winner, but there's meat left on the bone — top analyst
AbbVie has pinned much of its hopes in a post-Allergan merger future on recent immunology launches Skyrizi and Rinvoq, which are expected to offset the sales of a biosimilar Humira. To get there, both drugs will need big sales, and a boom in the rapidly growing IBD market could be just the ticket, one analyst writes.
The IBD market, which covers Crohn’s disease and ulcerative colitis, could be worth up to $32 billion in sales per year by 2025, nearly doubling its current value of around $18 billion, SVB Leerink analyst Geoffrey Porges wrote in a note to clients Tuesday.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 107,000+ biopharma pros reading Endpoints daily — and it's free.